Assembly Biosciences, Inc.
NASDAQ:ASMBBiotechnology
+$0.16 today
- Market cap
- $460.74M
- Beta
- 1.08
- P/E (TTM)
- -64.4
- EPS (TTM)
- -$0.38
Volume 0.33M
Average 0.17M
ASMB EBITDA Margin
EBITDA as a percentage of revenue.
Assembly Biosciences, Inc.NASDAQ: ASMB
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -110.2%
EBITDA Margin was -110.2% in Q1 FY2026, down 17.0 pp from a year earlier. On a trailing-twelve-month basis it was -8.8%, up 113.4 pp year over year.
Context
- EBITDA Margin widened in 2 of the last 2 fiscal years.
- FY2025 was the highest level in the 3 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -15.3% for the fiscal year ending Dec 2026, down from -8.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -110.2%-162.3 pp QoQ
- Last fiscal yearDec 2025
- -8.3%+131.0 pp YoY
- LTMMar 2026
- -8.8%+113.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -17.0 pp | -77.6 pp | -60.6 pp |
| 1 year | +131.0 pp | -7.0 pp | -138.0 pp |
| 3 years | — | -20.5 pp | — |
| 5 years | -1.9 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -8.3%
- Year-over-year change
- +131.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -8.3% | +131.0pp |
| FY2024 | 2024-12-31 | -139.3% | +708.8pp |
| FY2023 | 2023-12-31 | -848.0% | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | -1448.4% | — |
EBITDA Margin vs competitors
How ASMB compares with its peers on the latest reported figures
- ASMB's LTM Mar 2026 EBITDA Margin of -8.8% is the 2nd highest of the 4 companies compared; the peer median is -67.3%.
- Its year-over-year change of +113.4 pp is the 3rd highest of 4, against a peer median of +1306.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 84.0% | +1306.2 pp | -76.1 pp | |
| LTM Mar 2026 | -8.8% | +113.4 pp | — | |
| LTM Mar 2026 | -67.3% | +67.9 pp | +30.0 pp | |
| LTM Mar 2026 | -669.6% | +2109.2 pp | -668.6 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ASMB) | -67.3% | +1306.2 pp | -76.1 pp | |
Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.25M | 0 | 7.16M | 28.52M | 72.3M |
| Cost of Revenue | 0 | 69.08M | 48.9M | 55.93M | 129K |
| Gross Profit | 6.25M | (69.08M) | (41.74M) | (27.41M) | 72.17M |
| Gross Margin | 100.0% | — | -582.7% | -96.1% | 99.8% |
| Research & Development | 68.52M | 69.98M | 48.9M | 55.93M | 64.81M |
| Selling, General & Admin | 28.78M | 23.93M | 22.91M | 18.01M | 19.61M |
| Operating Expenses | 138.94M | 25.03M | 22.91M | 18.01M | 84.42M |
| Depreciation & Amortization | 466K | 498K | 450K | 129K | 129K |
| EBITDA | (90.58M) | (92.52M) | (60.75M) | (39.72M) | (5.99M) |
| EBITDA Margin | -1448.4% | — | -848.0% | -139.3% | -8.3% |
| Operating Income | (132.69M) | (94.11M) | (64.65M) | (45.42M) | (12.12M) |
| Operating Margin | -2121.7% | — | -902.5% | -159.3% | -16.8% |
| Interest Income | 302K | 1.02M | 3.45M | 5.57M | 6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 302K | 1.02M | 3.45M | 5.57M | 6M |
| Income Before Tax | (132.39M) | (93.09M) | (61.2M) | (39.85M) | (6.12M) |
| Pre-Tax Margin | -2116.8% | — | -854.3% | -139.7% | -8.5% |
| Income Tax Expense | (2.53M) | 0 | 33K | 330K | 0 |
| Net Income | (129.86M) | (93.09M) | (61.23M) | (40.18M) | (6.12M) |
| Net Margin | -2076.4% | — | -854.8% | -140.9% | -8.5% |
| EPS (Basic) | (36.00) | (22.82) | (13.38) | (6.69) | (0.55) |
| EPS (Diluted) | (36.00) | (22.82) | (13.38) | (6.69) | (0.55) |
| Weighted Avg Shares | 3.61M | 4.03M | 4.58M | 6M | 11.21M |
| Weighted Avg Shares (Diluted) | 3.61M | 4.03M | 4.58M | 6M | 11.21M |
Assembly Biosciences, Inc.
NASDAQ:ASMB
Intrinsic Alpha fair value
Locked
Current Price
$22.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.